Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
Richard S FinnMasatoshi KudoAnn-Lii ChengLucjan WyrwiczRoger K-C NganJean-Frederic BlancAri D BaronArndt VogelMasafumi IkedaPiscaglia FabioKwang-Hyub HanShukui QinYukinori MinoshimaMichio KanekiyoMin RenRyo DairikiToshiyuki TamaiCorina E DutcusHiroki IkezawaYasuhiro FunahashiThomas R Jeffry EvansPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Higher baseline levels of VEGF, FGF21, and ANG2 may be prognostic for shorter OS. Higher baseline FGF21 may be predictive for longer OS with lenvatinib compared with sorafenib, but this needs confirmation.